文献速递肺结节与肺癌

病理单站与多站淋巴结描述符在可切除非小细胞肺癌中的作用

Role of Pathologic Single-Nodal and Multiple-Nodal Descriptors in Resected Non-Small Cell Lung Cancer.
PubMed 文献 · Chest · 2024-07-14

基于美国国家癌症数据库分析病理N1和N2非小细胞肺癌患者,比较病理单枚与多枚淋巴结转移的预后分层价值。

要点

  • 病理多枚N1或N2转移者生存分别短于单枚N1或N2转移者(HR 1.22/1.39)。

核心结论

  • 非小细胞肺癌患者无论N1或N2站,仅一枚淋巴结转移者生存优于多枚淋巴结转移者。
  • 单站跳跃N2转移患者生存与多枚N1转移患者相似。
  • N1站转移淋巴结数目至4枚及以上呈依次预后分层。

研究设计与样本

  • 使用美国国家癌症数据库分析病理分期N1和N2的非小细胞肺癌患者。
  • 淋巴结描述符分为病理单枚N1、多枚N1、单枚N2和多枚N2。
  • 采用Kaplan-Meier法和多因素Cox回归模型进行生存分析。
  • 敏感性分析队列限R0切除、肺叶切除或更大范围、生存≥30天、≥10枚受检淋巴结且无新辅助治疗(n=34,904)。
  • 外部验证队列n=708。

主要发现

  • 一般分析队列中,病理单枚N1、多枚N1、单枚N2和多枚N2患者分别为24,531、22,256、8,528和21,949例。
  • 敏感性分析和外部验证队列分析支持上述结果。

临床怎么用

  • 病理报告应明确区分单枚与多枚淋巴结转移及N1站转移淋巴结计数,以辅助预后分层。
  • 单站跳跃N2转移的预后可能与多枚N1转移相近,提示需综合评估淋巴结转移负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The eighth edition of lung cancer nodal staging assignment includes the location of lymph node metastasis, but does not include single-nodal and multiple-nodal descriptors. RESEARCH QUESTION: Do the single-nodal and multiple-nodal statuses stratify the prognosis of patients with non-small cell lung cancer (NSCLC)? STUDY DESIGN AND METHODS: Using the National Cancer Database, we analyzed patients with pathologically staged N1 and N2 NSCLC. Nodal descriptors were classified into pathological single N1 (pSingle-N1), pathological multiple N1 (pMulti-N1), pathological single N2 (pSingle-N2), and pathological multiple N2 (pMulti-N2). Survival analysis was performed using the Kaplan-Meier method and multivariable Cox regression models. RESULTS: In the general analysis cohort, 24,531, 22,256, 8,528, and 21,949 patients with NSCLC demonstrated pSingle-N1, pMulti-N1, pSingle-N2, and pMulti-N2 disease, respectively. Patients with pMulti-N1 and pMulti-N2 disease showed a shorter survival than those with pSingle-N1 and pSingle-N2 disease, respectively (hazard ratio, 1.22 [P < .0001] for N1 and 1.39 [P < .0001] for N2). After adjusting age, sex, and histologic findings, the hazard ratio for pSingle-N2 compared with pMulti-N1 disease was 1.05 (P = .0031). Patients with pN1 disease were categorized by metastatic lymph node count (1, 2, 3, ≥ 4), showing significant prognostic differences among groups (P < .0001). In the sensitivity analysis cohort (limited to R0 resection, lobectomy, or more; survival ≥ 30 days; ≥ 10 examined lymph nodes; and without neoadjuvant therapy; n = 34,904) and the external validation cohort (n = 708), analyses supported these results. INTERPRETATION: Patients with NSCLC with one metastatic lymph node, whether in N1 or N2 stations, showed better survival than those with more than one lymph node involved. Patients with NSCLC with a single-skip N2 lymph node metastasis showed survival similar to patients with multiple N1 lymph nodes, and the number of lymph nodes involved in N1 resections up to four or more was sequentially prognostic.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Takamori S, Osoegawa A, Hashinokuchi A, et al. Role of Pathologic Single-Nodal and Multiple-Nodal Descriptors in Resected Non-Small Cell Lung Cancer. Chest. 2024. PMID: 39004218. doi:10.1016/j.chest.2024.06.3797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。